DOCSLIB.ORG

Beta2-Adrenergic Receptor Agonists: a Comparison of Reproterol, Fenoterol and Salbutamol on Monocyte Cyclic-Amp and Leukotriene B4 Production in Vitro

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Beta2-Adrenergic Receptor Agonists: a Comparison of Reproterol, Fenoterol and Salbutamol on Monocyte Cyclic-Amp and Leukotriene B4 Production in Vitro July 30, 2004 EUROPEAN JOURNAL OF MEDICAL RESEARCH 365 Eur J Med Res (2004) 9: 365-370 © I. Holzapfel Publishers 2004 DIFFERENT MECHANISMS OF ACTION OF BETA2-ADRENERGIC RECEPTOR AGONISTS: A COMPARISON OF REPROTEROL, FENOTEROL AND SALBUTAMOL ON MONOCYTE CYCLIC-AMP AND LEUKOTRIENE B4 PRODUCTION IN VITRO U. R. Juergens1, M. Stöber1, H. Libertus2, W. Darlath3, A. Gillissen4, H. Vetter1 1Department of Pneumology, Medical Outpatient Clinic, Bonn University Hospital, Germany; 2VIATRIS, Frankfurt Clinical Development, Germany, 3Aventis Pharma Germany, Clinical Development, Bad Soden, Germany; 4St. George Medical Center, Robert-Koch-Hospital, Leipzig, Germany Abstract INTRODUCTION Background: Beta2-adrenergic receptor agonists have several effects on airway function, most of which are Asthma treatment is based on anti-inflammatory and mediated in a variety of cell types resulting in in- bronchodilator therapy [19]. Beta2-adrenergic recep- creased c-AMP-production and inhibition of inflam- tor agonists act as potent smooth muscle relaxants matory mediator production. However, their stimulat- and are important drugs for the relief of acute asth- ing effects on cAMP-production became known to be matic bronchoconstriction. In addition, they are able inversed by increasing phosphodiesterase (PDE) activ- to inhibit the release of inflammatory mediators in ity and degradation of cAMP. Therefore, in this study leukocytes and airway cells, such as histamine and we have evaluated the efficacy of reproterol, a dual leukotrienes from mast cells [4] and therefore may acting beta2-adrenoceptor agonist and PDE-inhibitor, play a role in suppressing the acute asthmatic inflam- as compared to salbutamol and fenoterol with respect matory reaction [1]. Beta 2-adrenergic receptor ago- to production of cAMP and LTB4 in cultured mono- nists act by stimulating the intracellular activity of cytes. adenylyl cyclase resulting in increased production of Methods: Isolated human monocytes (10 5/ml) were in- cyclic adenosine monophosphate (cAMP) [20]. Cyclic- cubated (n = 9) in suspension with beta2-adrenocep- AMP plays an important regulatory role in many cell tor agonists (10 -10-10 -4M) for 30 minutes with and types involved in the pathophysiology of asthma. It without IBMX. Then, cAMP production was deter- suppresses the activity of immune and inflammatory mined following treatment with Triton-X100. Produc- cells and leads to acute relaxation of airway smooth tion of LTB4 was measured following incubation of muscles [25]. beta2-adrenoceptor agonists for 4 hrs in the presence The bronchodilator reproterol is a monomolecular of LPS (10 mg/ml). cAMP and LTB4 were measured in compound synthesised by combination of the non-se- culture supernatants by enzyme immunoassay. lective beta-agonist orciprenaline (known in the US as Results: At 10 -5 M, production of cAMP was signifi- metaproterenol) and the xanthine derivative theo- cantly stimulated by reproterol > fenoterol > salbuta- phylline [8]. We could recently show that reproterol mol in a dose-dependent manner to an extent of stimulates cAMP and inhibits leukotriene B4 (LTB4) *128%, *65%, 13% (*p<0.04) respectively. In contrast, production in cultured monocytes in vitro [10]. The LTB4-production was inhibited significantly to a simi- effects exerted by reproterol were greater than those lar degree by salbutamol and reproterol in a dose-de- of each of its constituents alone, probably due to a pendent manner by 59% and 49% (10 -5M, p<0.03), re- synergistic action of the orciprenaline and the theo- spectively, with decreasing inhibition (15%) after phylline component of the molecule on adenylyl cy- fenoterol. Following co-incubation with IBMX, cAMP clase and phosphodiesterase enzymes. These results production only increased significantly (p<0.002) after are of interest as a combination of reproterol and sodi- fenoterol (+110%) compared to salbutamol (+29%) um cromoglycerate is used for asthma therapy in Ger- and reproterol (+50%) (ANOVA, p<0.001). many. In a clinical trial, the protective effects of the Conclusion: These data suggest effects of the theo- fixed drug combination of inhaled reproterol and sodi- phylline constituent of reproterol to inhibit adenylyl um cromoglycate in exercise-induced asthma com- cyclase induced phosphodiesterase activity. The advan- pared to both substances alone were superior suggest- tageous synergistic effects of reproterol on cAMP- ing the use of a combination of reproterol and sodium production need to be further explored in trials. cromoglycerate in exercise-induced asthma on children and adults [2]. This peculiar importance of reproterol Key words: asthma, reproterol, salbutamol, fenoterol, compared to salbutamol and fenoterol may be of fur- cAMP, leukotriene B4. ther interest. 366 EUROPEAN JOURNAL OF MEDICAL RESEARCH July 30, 2004 We have now examined two selective beta2-adreno- ceptor agonists, salbutamol and fenoterol, in order to further determine the potential role of the theo- phylline component of the reproterol molecule. We aimed at investigating whether reproterol is more po- tent than salbutamol or fenoterol with respect to in- creasing cAMP levels and related suppression of LTB4-production in cultured human monocytes. METHODS Six healthy non-smoking volunteers (age: 25 ± 5 years) with no history of asthma or atopic disease agreed to donate 60 ml of blood for each experiment. Monocytes were isolated by gradient centrifugation as previously described (Nycodenz Monocytes, 1.068 Fig. 1. Increased stimulation of cAMP-production with repro- g/l) resulting in platelet-free samples of 2-3x10 6 cells terol compared to fenoterol and salbutamol in vitro. In cul- with a purity of >95% as assessed by light microscopy tured monocytes, spontaneous cAMP-production (n = 9) was [3]. Cell vitality was >98% as determined by trypan increased significantly (*p<0.04) more by reproterol (10-5M, blue exclusion and lactate dehydrogenase (LDH) activ- 10-4M) compared to fenoterol or salbutamol. At 10-6 M ef- ity (Boehringer Ingelheim, Germany). fects of fenoterol or salbutamol were not significantly differ- Effects of reproterol (Bronchospamin®, VIATRIS, ent (**p = 0.08, ANOVA) compared to reproterol. Frankfurt, Germany), salbutamol and fenoterol (Sig- ma) were determined following incubation of mono- cytes (10 5/ml) cultured for 30 minutes in suspension. For the measurement of cAMP cells were made per- meable in the presence of Triton-X100 (0.25 mM/ 10 min, Sigma). Monocytes were thereafter pelleted by centrifugation (500 g for 5 minutes at 4°C) and the su- pernatants were harvested and immediately frozen in liquid nitrogen and stored at -80°C until assayed. Ex- periments were repeated after non-specific inhibition of phosphodiesterases with IBMX (preincubation of 10 5 cells/ml with 0.25 x 10 -3M IBMX, Sigma, for 5 minutes). For the determination of LTB4-production, aliquots of monocytes (10 5/ml) were incubated with an optimal concentration of lipopolysaccharide (10µg/ml, LPS) and the test substance on 48-well- plates (Costar) for 4 hours at 37°C in RPMI 1640 con- taining 10% foetal calf serum. LTB4 and cAMP were measured in the culture su- pernatants by direct enzyme immunoassay as previ- ously described [9] -(materials purchased from Cay- man Chem. Corp., Ann Arbor, Michigan, USA; mi- Fig. 2. Stimulation of cAMP production by beta2-adrenergic crotiter plates from Nunc, Kamstrup, Denmark). receptor agonists following PDE-inhibition. Production of cAMP was measured after incubation of normal monocytes STATISTICAL ANALYSIS (105/ml) for 30 min. with IBMX (0.25 X 10-3 M) and beta2- adrenergic receptor agonists. Stimulation of cAMP produc- All results are expressed as means ± standard errors of tion following PDE-inhibition was greater for fenoterol than the means (SEM) for triplicate cultures of 3-4 experi- for reproterol and salbutamol but did not significantly in- ments, if not mentioned otherwise. Mann Whitney U crease after salbutamol (*p<0.03, **p<0.09). nonparametric tests, paired t-tests and ANOVA were used where appropriate for statistical comparisons of drug effects with the control and different beta2-ago- dose-dependent increase from 24 ± 16% at 10 -7M nists. P-values were considered significant if <0.05. All (p>0.05) to 414 ± 14% at 10 -4M as compared to the analyses were performed using the StatView 5.01 soft- control (p = 0.0012, Fig. 1, Table 1). Fenoterol and ware (SAS Institute Inc., Cary, NC, USA) for Macin- salbutamol exerted much smaller effects compared to tosh computers. the control with maximum values of 65 ± 23% at 10 -5M fenoterol and of 22 ± 3% at 10 -4M salbutamol, RESULTS respectively. These effects, however, were not statisti- cally significant (Table 1). Stimulation of cAMP-pro- CAMP-PRODUCTION duction by reproterol (10 -5M, 10 -4M) was significantly After reproterol had been added to the test system, greater than after salbutamol or fenoterol (n = 9, p = production of cAMP (n = 9) by monocytes showed a 0.0002 by ANOVA). July 30, 2004 EUROPEAN JOURNAL OF MEDICAL RESEARCH 367 Table 1. Increase of spontaneous cAMP production in cultured monocytes after incubation with reproterol (n = 9), salbutamol (n = 7) and fenoterol (n = 9) without IBMX in percent. Reproterol Salbutamol Fenoterol M/30min cAMP *Effect p-value cAMP *Effect p-value cAMP *Effect p-value (pg/105)(%) (pg/105)(%) (pg/105)(%) Baseline 1.064 - - 1.433 - - 1.114 - - ±0.19 ±0.03 ±0.179 10-9 1.095 2.9 0.7963 1.3 -9.3 0.4386 1.341 20.9 0.8137 ±0.334 ±30 ±0.03 ±2 ±0.153 ±11 10-8 0.896 -15.8 1 1.328 -7.3 0.6056 1.182 6.1 0.711 ±0.283 ±31 ±0.083 ±6.2 ±0.061 ±5 10-7 1.317 23.8 0.1826 1.451 1.2 1 1.4 25.6 0.191 ±0.208 ±16 ±0.086 ±6 ±0.229 ±16 10-6 1.575 48 0.1307 1.692 18.7 0.0865 1.511 35.6 0.1912 ±0.285 ±18 ±0.089 ±5 ±0.276 ±18 10-5 2.42 127.4 0.0012 1.618 12.9 0.2833 1.843 65.4 0.0833 ±0.187 ±8 ±0.119 ±7 ±0.349 ±23 10-4 5.479 414.9 0.0012 1.75 22.1 0.055 1.632 46.5 0.4629 ±0.776 ±14 ±0.054 ±3 ±0.583 ±36 = % change from control Table 2.
Load more

Recommended publications
  • Molecular Signatures of G-Protein-Coupled Receptors A
    REVIEW doi:10.1038/nature11896 Molecular signatures of G-protein-coupled receptors A. J. Venkatakrishnan1, Xavier Deupi2, Guillaume Lebon1,3,4,5, Christopher G. Tate1, Gebhard F. Schertler2,6 & M. Madan Babu1 G-protein-coupled receptors (GPCRs) are physiologically important membrane proteins that sense signalling molecules such as hormones and neurotransmitters, and are the targets of several prescribed drugs. Recent exciting developments are providing unprecedented insights into the structure and function of several medically important GPCRs. Here, through a systematic analysis of high-resolution GPCR structures, we uncover a conserved network of non-covalent contacts that defines the GPCR fold. Furthermore, our comparative analysis reveals characteristic features of ligand binding and conformational changes during receptor activation. A holistic understanding that integrates molecular and systems biology of GPCRs holds promise for new therapeutics and personalized medicine. ignal transduction is a fundamental biological process that is comprehensively, and in the process expand the current frontiers of required to maintain cellular homeostasis and to ensure coordi- GPCR biology. S nated cellular activity in all organisms. Membrane proteins at the In this analysis, we objectively compare known structures and reveal cell surface serve as the communication interface between the cell’s key similarities and differences among diverse GPCRs. We identify a external and internal environments. One of the largest and most diverse consensus structural scaffold of GPCRs that is constituted by a network membrane protein families is the GPCRs, which are encoded by more of non-covalent contacts between residues on the transmembrane (TM) than 800 genes in the human genome1. GPCRs function by detecting a helices.
    [Show full text]
  • Emerging Evidence for a Central Epinephrine-Innervated A1- Adrenergic System That Regulates Behavioral Activation and Is Impaired in Depression
    Neuropsychopharmacology (2003) 28, 1387–1399 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Perspective Emerging Evidence for a Central Epinephrine-Innervated a1- Adrenergic System that Regulates Behavioral Activation and is Impaired in Depression ,1 1 1 1 1 Eric A Stone* , Yan Lin , Helen Rosengarten , H Kenneth Kramer and David Quartermain 1Departments of Psychiatry and Neurology, New York University School of Medicine, New York, NY, USA Currently, most basic and clinical research on depression is focused on either central serotonergic, noradrenergic, or dopaminergic neurotransmission as affected by various etiological and predisposing factors. Recent evidence suggests that there is another system that consists of a subset of brain a1B-adrenoceptors innervated primarily by brain epinephrine (EPI) that potentially modulates the above three monoamine systems in parallel and plays a critical role in depression. The present review covers the evidence for this system and includes findings that brain a -adrenoceptors are instrumental in behavioral activation, are located near the major monoamine cell groups 1 or target areas, receive EPI as their neurotransmitter, are impaired or inhibited in depressed patients or after stress in animal models, and a are restored by a number of antidepressants. This ‘EPI- 1 system’ may therefore represent a new target system for this disorder. Neuropsychopharmacology (2003) 28, 1387–1399, advance online publication, 18 June 2003; doi:10.1038/sj.npp.1300222 Keywords: a1-adrenoceptors; epinephrine; motor activity; depression; inactivity INTRODUCTION monoaminergic systems. This new system appears to be impaired during stress and depression and thus may Depressive illness is currently believed to result from represent a new target for this disorder.
    [Show full text]
  • Validation of New Analytical Methodology for Determining Fenoterolhydrobromide by HPLC: Application in Pharmaceutical Products
    Artigo Original/Original Article Validation of new analytical methodology for determining fenoterolhydrobromide by HPLC: application in pharmaceutical products Validação de uma nova metodologia analítica para determinação de bromidrato de fenoterol por CLAE: aplicações em produtos farmacêuticos RIALA6/1475 *Helena Miyoco YANO1, Fernanda Fernandes FARIAS1, Marcelo Beiriz DEL BIANCO1, Pedro Lopez GARCIA2 *Endereço para correspondência: 1Núcleo de Ensaios Físicos e Químicos em Medicamentos, Centro de Medicamentos, Cosméticos e Saneantes, Instituto Adolfo Lutz, Av. Doutor Arnaldo, 355, CEP: 01246-902, São Paulo, SP, Brasil. E-mail: [email protected] 2Departamento de Farmácia, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, SP, Brasil. Recebido: 31.10.2011- Aceito para publicação: 20.04.2012 RESUMO Bromidrato de fenoterol é um agente agonista adrenérgico β2-seletivo utilizado para tratamento de asma e doenças pulmonares crônicas obstrutivas. A metodologia analítica por cromatografia líquida de alta eficiência (CLAE) foi desenvolvida e validada para a determinação quantitativa de bromidrato de fenoterol. A condição analítica empregada incluiu coluna em fase reversa C18 (150 mm × 3,9 mm d.i., 5 µm) Thermo®, fase móvel composta de mistura de acetonitrila e água (30:70, v/v) com 0,1% de trietilamina e pH ajustado para 5,0 com ácido fórmico, vazão de 1,0 mL.min-1 e detecção em UV a 276 nm. A faixa de linearidade foi de 0,025 a 0,15 mg.mL-1; a curva analítica mostrou coeficiente de correlação > 0,999. O limite de detecção (LD) foi de 0,003 mg.mL-1 e o limite de quantificação de 0,012 mg.mL-1.
    [Show full text]
  • Ep 2560611 B1
    (19) TZZ Z___T (11) EP 2 560 611 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) 03.01.2018 Bulletin 2018/01 (86) International application number: (21) Application number: 11719211.2 PCT/EP2011/056227 (22) Date of filing: 19.04.2011 (87) International publication number: WO 2011/131663 (27.10.2011 Gazette 2011/43) (54) "PROCESS FOR PROVIDING PARTICLES WITH REDUCED ELECTROSTATIC CHARGES" VERFAHREN ZUR BEREITSTELLUNG VON PARTIKELN MIT REDUZIERTEN ELEKTROSTATISCHEN LADUNGEN PROCÉDÉ DE PRÉPARATION DE PARTICULES AYANT DES CHARGES ÉLECTROSTATIQUES RÉDUITES (84) Designated Contracting States: • GUCHARDI ET AL: "Influence of fine lactose and AL AT BE BG CH CY CZ DE DK EE ES FI FR GB magnesium stearate on low dose dry powder GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO inhaler formulations", INTERNATIONAL PL PT RO RS SE SI SK SM TR JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL LNKD- DOI:10.1016/J.IJPHARM.2007.06.041, (30) Priority: 21.04.2010 EP 10160565 vol. 348, no. 1-2, 19 December 2007 (2007-12-19), pages 10-17, XP022393884, ISSN: 0378-5173 (43) Date of publication of application: • ELAJNAF A ET AL: "Electrostatic 27.02.2013 Bulletin 2013/09 characterisation of inhaled powders: Effect of contact surface and relative humidity", (73) Proprietor: Chiesi Farmaceutici S.p.A. EUROPEAN JOURNAL OF PHARMACEUTICAL 43100 Parma (IT) SCIENCES, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/J.EJPS.2006.07.006, vol. 29, no. 5, 1 (72) Inventors: December 2006 (2006-12-01), pages 375-384, • COCCONI, Daniela XP025137181, ISSN: 0928-0987 [retrieved on I-43100 Parma (IT) 2006-12-01] • MUSA, Rossella • CHAN ET AL: "Dry powder aerosol drug I-43100 Parma (IT) delivery-Opportunities for colloid and surface scientists", COLLOIDS AND SURFACES.
    [Show full text]
  • Covalent Agonists for Studying G Protein-Coupled Receptor Activation
    Covalent agonists for studying G protein-coupled receptor activation Dietmar Weicherta, Andrew C. Kruseb, Aashish Manglikb, Christine Hillera, Cheng Zhangb, Harald Hübnera, Brian K. Kobilkab,1, and Peter Gmeinera,1 aDepartment of Chemistry and Pharmacy, Friedrich Alexander University, 91052 Erlangen, Germany; and bDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305 Contributed by Brian K. Kobilka, June 6, 2014 (sent for review April 21, 2014) Structural studies on G protein-coupled receptors (GPCRs) provide Disulfide-based cross-linking approaches (17, 18) offer important insights into the architecture and function of these the advantage that the covalent binding of disulfide-containing important drug targets. However, the crystallization of GPCRs in compounds is chemoselective for cysteine and enforced by the active states is particularly challenging, requiring the formation of affinity of the ligand-pharmacophore rather than by the elec- stable and conformationally homogeneous ligand-receptor com- trophilicity of the cross-linking function (19). We refer to the plexes. Native hormones, neurotransmitters, and synthetic ago- described ligands as covalent rather than irreversible agonists nists that bind with low affinity are ineffective at stabilizing an because cleavage may be promoted by reducing agents and the active state for crystallogenesis. To promote structural studies on disulfide transfer process is a reversible chemical reaction the pharmacologically highly relevant class
    [Show full text]
  • ADD/ADHD: Strattera • Allergy/Anti-Inflammatories
    EXAMPLES OF PERMITTED MEDICATIONS - 2015 ADD/ADHD: Strattera Allergy/Anti-Inflammatories: Corticosteroids, including Decadron, Depo-Medrol, Entocort, Solu-Medrol, Prednisone, Prednisolone, and Methylprednisolone Anesthetics: Alcaine, Articadent, Bupivacaine HCI, Chloroprocaine, Citanest Plain Dental, Itch-X, Lidocaine, Marcaine, Mepivacaine HCI, Naropin, Nesacaine, Novacain, Ophthetic, Oraqix, Paracaine, Polocaine, Pontocaine Hydrochloride, PrameGel, Prax, Proparacaine HCI, Ropivacaine, Sarna Ultra, Sensorcaine, Synera, Tetracaine, Tronothane HCI, and Xylocaine Antacids: Calci-Chew, Di-Gel, Gaviscon, Gelusil, Maalox, Mintox Plus, Mylanta, Oyst-Cal 500, Rolaids, and Tums Anti-Anxiety: Alprazolam, Atarax, Ativan, Buspar, Buspirone HCI, Chlordiazepoxide HCI, Clonazepam, Chlorazepate Dipotassium, Diastat, Diazepam, Hydroxyzine, Klonopin, Librium, Lorazepam, Niravam, Tranxene T-tab, Valium, Vistaril, and Xanax Antibiotics: Acetasol HC, Amoxil, Ampicillin, Antiben, Antibiotic-Cort, Antihist, Antituss, Avelox, Ceftazidime, Ceftin, Cefuroxime Axetil, Ceptaz, Cleocin, Cloxapen, Cortane-B Aqueous, Cortic, Cresylate, Debrox, Doryx, EarSol-HC, Fortaz, Gantrisin, Mezlin, Moxifloxacin, Neotic, Otocain, Principen, Tazicef, Tazidime, Trioxin, and Zyvox Anti-Depressants: Adapin, Anafranil, Asendin, Bolvidon, Celexa, Cymbalata, Deprilept, Effexor, Elavil, Lexapro, Luvox, Norpramin, Pamelor, Paxil, Pristiq, Prozac, Savella, Surmontil, Tofranil, Vivactil, Wellbutrin, Zoloft, and Zyban Anti-Diabetics: Actos, Amaryl, Avandia, Glipizide, Glucophage,
    [Show full text]
  • Ep 2626065 A1
    (19) TZZ Z_T (11) EP 2 626 065 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC (43) Date of publication: (51) Int Cl.: A61K 31/137 (2006.01) A61K 31/135 (2006.01) 14.08.2013 Bulletin 2013/33 A61K 31/4704 (2006.01) A61K 31/58 (2006.01) A61K 31/56 (2006.01) A61K 9/12 (2006.01) (2006.01) (2006.01) (21) Application number: 11827927.2 A61K 9/14 A61P 11/06 (86) International application number: Date of filing: 01.02.2011 (22) PCT/CN2011/070883 (87) International publication number: WO 2012/041031 (05.04.2012 Gazette 2012/14) (84) Designated Contracting States: (72) Inventor: WU, Wei-hsiu AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Taipei GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Taiwan (TW) PL PT RO RS SE SI SK SM TR (74) Representative: Patentanwaltskanzlei WILHELM (30) Priority: 28.09.2010 CN 201010502339 & BECK Prinzenstrasse 13 (71) Applicant: Intech Biopharm Ltd. 80639 München (DE) Taipei (TW) (54) COMPOUND COMPOSITION FOR INHALATION USED FOR TREATING ASTHMA (57) An inhaled pharmaceutical composition con- tric way as a controller. The eccentric way control therapy tains primary active ingredients of beta2- agonist and cor- could create a low blood concentration period during the ticosteroids.The pharmaceuticalcompositions disclosed day and minimize the acute tolerance phenomenon (or in the present invention are to be inhaled by a patient so called tachyphylaxis) for bronchodilator - beta2-ago- when needed as a reliever, or administrated in an eccen- nists in treating asthma or other obstructive respiratory disorders.
    [Show full text]
  • 5 August 2004 Version
    The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. Study No.: SAM 30020 Title: Efficacy and tolerability of the salmeterol/fluticasone 50/100 mcg combination Diskus, inhaled once daily in the evening, in comparison to the p.r.n. inhalation from the reproterol/sodium cromoglycate 0.5/ 1 mg combination MDI, as initial therapy for patients with mild asthma – a multicentre, randomised, open, parallel trial Rationale: The reproterol/sodium cromoglycate 0.5/ 1 mg combination is still widely used for the treatment of mild asthmatics. Usually, patients inhale the combination product from an MDI, and they adjust the dosage according to their asthma symptoms. Anti-inflammatory medication with an inhaled corticosteroid such as fluticasone is an alternative therapeutic option, and long-acting beta agonists can be used as bronchodilatory treatment. The study aimed to investigate whether the efficacy of the salmeterol/fluticasone 50/100-mcg combination (SFC), inhaled from the Diskus once daily in the evening, is superior to that of the PRN inhalation of the reproterol/sodium cromoglycate 0.5/ 1 mg combination (RS) from the metered dose inhaler. Phase: IV Study Period: 13 June 2002 to 27 June 2003 Study Design: This randomised, prospective, open, parallel group study had a total duration of ten weeks. There were two study periods: a run-in period of two weeks, and a treatment period of 8 weeks.
    [Show full text]
  • Application Number
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 203975s000 SUMMARY REVIEW SUMMARY REVIEW OF REGULATORY ACTION Date: November 26, 2013 From: Badrul A. Chowdhury, MD, PhD Director, Division of Pulmonary, Allergy, and Rheumatology Products, CDER, FDA Subject: Division Director Summary Review NDA Number: 20-3975 Applicant Name: GlaxoSmithKline Date of Submission: December 18, 2012 PDUFA Goal Date: December 18, 2013 Proprietary Name: Anoro Ellipta Established Name: Umeclidinium and vilanterol Dosage form: Inhalation Powder (inhaler contains 2 double-foil blister strips, each with 30 blisters containing powder for oral inhalation) Strength: Umeclidinium 62.5 mcg per blister and vilanterol 25 mcg per blister Proposed Indications: Maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD) Action: Approval 1. Introduction GlaxoSmithKline (GSK) submitted this 505(b)(1) new drug application for use of Anoro Ellipta (umeclidinium 62.5 mcg and vilanterol 25 mcg inhalation powder) for long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). The proposed dose is one inhalation (umeclidinium 62.5 mcg and vilanterol 25 mcg) once daily. The application is based on clinical efficacy and safety studies. This summary review will provide an overview of the application, with a focus on the clinical efficacy and safety studies. 2. Background There are several drug classes available for the relief of airflow obstruction in patients with COPD. These include short- and long-acting beta-2 adrenergic agonists, short- and long-acting anticholinergics, combination products containing beta-2 adrenergic agonists and anticholinergics, combination of long-acting beta-2 adrenergic agonists and corticosteroids, methylxanthines, and phosphodiesterase-4 (PDE4) inhibitors.
    [Show full text]
  • Original Research Bethanecol Chloride for Treatment of Clomipramine
    REV. HOSP. CLÍN. FAC. MED. S. PAULO 59(6):357-360, 2004 ORIGINAL RESEARCH BETHANECOL CHLORIDE FOR TREATMENT OF CLOMIPRAMINE-INDUCED ORGASMIC DYSFUNCTION IN MALES Márcio Bernik, Antonio Hélio Guerra Vieira and Paula Villela Nunes BERNIK M et al. Bethanecol chloride for treatment of clomipramine-induced orgasmic dysfunction in males. Rev. Hosp. Clin. Fac. Med. S. Paulo 59(6):357-360, 2004. PURPOSE: To investigate whether bethanecol chloride may be an alternative for the clinical management of clomipramine-induced orgasmic dysfunction, reported to occur in up to 96% of male users. METHODS: In this study, 12 fully remitted panic disorder patients, complaining of severe clomipramine-induced ejaculatory delay, were randomly assigned to either bethanecol chloride tablets (20 mg, as needed) or placebo in a randomized, double-blind, placebo-controlled, two-period crossover study. A visual analog scale was used to assess severity of the orgasmic dysfunction. RESULTS: A clear improvement was observed in the active treatment period. No placebo or carry-over effects were observed. CONCLUSION: These findings suggest that bethanecol chloride given 45 minutes before sexual intercourse may be useful for clomipramine-induced orgasmic dysfunction in males. KEYWORDS: Orgasmic dysfunction. Clomipramine. Bethanecol chloride. Panic disorder. Pharmacological treatment. In panic disorder patients, effective clude the following: 1) increased brain side effects such as orgasmic dysfunc- pharmacological treatment with anti- serotonin, particularly affecting 5TH2 tion in up to 20% to 96% of pa- depressants has been shown to greatly and 5HT3 receptors; 2) decreased tients.5,6,13 improve the quality of life, but it is of- dopamine; 3) central blockade of Clomipramine is the imipramine ten associated with the emergence of cholinergic and alpha-1 adrenergic analogue of chlorpromazine.
    [Show full text]
  • Orciprenaline Sulphate (Alupent): Planned Withdrawal from the UK Market Following a Risk-Benefit Analysis
    MHRA PUBLIC ASSESSMENT REPORT Orciprenaline sulphate (Alupent): planned withdrawal from the UK market following a risk-benefit analysis November 2009 Executive summary 2 1. Introduction 3 2. Summary of data 3 2.1 Clinical pharmacology 3 2.2 Efficacy 3 2.3 Safety 4 3. Conclusions 8 4. References 9 5. Glossary 10 1 EXECUTIVE SUMMARY (Please note that this summary is intended to be accessible to all members of the public, including health professionals) Background The Medicines and Healthcare products Regulatory Agency (MHRA) is the government agency responsible for regulating the effectiveness and safety of medicines and medical devices in the UK. We continually review the safety of all medicines in the UK, and inform healthcare professionals and the public of the latest safety updates. In our Public Assessment Reports, we discuss the evidence for a safety issue with a particular drug or drug class, and changes made to the product information for the drug on the basis of this evidence, which will help safeguard public health. This MHRA Public Assessment Report discusses a review of the risks and benefits of a medicine called orciprenaline sulphate. Orciprenaline sulphate is available for oral administration as a syrup used to treat reversible airways obstructiona, which is a symptom of asthmab and chronic obstructive pulmonary diseasec. It acts on specific areas in the body called β- receptors, which relaxes the muscles used for breathing and opens the airways in the lungs. Orciprenaline sulphate was licensed in 1972 and is marketed in the UK under the brand name Alupent Syrup. As with any medicine, the use of orciprenaline sulphate may lead to adverse reactions (side-effects) in some individuals, which are described in the product information, including the patient information leaflet (see the Electronic Medicines Compendium (product information) website).
    [Show full text]
  • Case-Control Study Ofprescribed Fenoterol
    170 Thorax 1990;45:170-175 Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81 Thorax: first published as 10.1136/thx.45.3.170 on 1 March 1990. Downloaded from N Pearce, J Grainger, M Atkinson, J Crane, C Burgess, C Culling, H Windom, R Beasley Abstract A recent New Zealand case-control study,' A previous New Zealand case-control conducted by our group, tested the hypothesis study of asthma deaths in the 5-45 year that the unsupervised self administration of age group during 1981-3 found that pres- fenoterol by inhalation increases the risk of cription of fenoterol (by metered dose death from asthma. This hypothesis arose inhaler) was associated with an increased primarily from epidemiological evidence link- risk of death in patients with severe ing the sale of fenoterol to the epidemic of asthma. One major criticism ofthis study deaths from asthma that New Zealand has was that drug data for the cases and experienced since the late 1970s,' 2 and controls came from different sources. A experimental evidence that fenoterol is a less new case-control design has been used to selective beta2 agonist than salbutamol, the evaluate the same hypothesis, with a dif- most commonly used beta agonist.3 The possi- ferent set of asthma deaths, the same ble mechanisms ofaction remain to be clarified, source for drug information being used but several potential mechanisms are apparent; for both cases and controls. This depen- these depend on whether the association is with ded on identifying deaths from asthma long term use of fenoterol or use in the acute during 1977-81 from national mortality attack.
    [Show full text]